Introduction
============

Colorectal cancer (CRC) ranks as the third most frequent cancer in men and second in women worldwide [@B1]. Rectal cancers approximately accounts for one-third of CRC and significant effort has been done to achieve better treatment results [@B2]. Neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery remains the preferred therapy for patients with locally advanced rectal cancer LARC, resulting in better sphincter preservation rates and superior survival [@B3]-[@B6]. Nevertheless, up to 15-20% of these patients receiving neoadjuvant CCRT will eventually develop local recurrence or distant metastases [@B7], [@B8]. Therefore, it could be of clinical implication in identifying prognostic biomarkers of LARC in response to CCRT as well as risk stratification for further treatment and development of novel target therapies.

Ion transport across the cell membrane plays an important role in many cellular functions such as cell proliferation, migration and cell death [@B9]-[@B12]. In recent years, it has become more clearly that ion transporters and channels participate in the regulation of cancer development and are critically important for tumor cell survival and metastasis [@B10]-[@B13]. It might have important implications in targeting ion transporters identifying prognostic biomarkers as well as developing suitable therapeutic targets. Therefore, we performed data mining from a published transcriptome of rectal cancers (GSE35452), identifying Transcobalamin I (*TCN1*) gene as the most significantly upregulated gene among the pathways associated with ion transport-related genes (GO:0006811).

TCN1 \[haptocorrin or vitamin B12 (cobalamin) R binder\], is one of the three transport proteins that binds vitamin B12 and is present in human serum and various biological fluids [@B14]. As we know, vitamin B12 plays an important role in maintenance of nervous system function, hematopoiesis, and cell metabolism [@B14]-[@B16]. TCN1 carries vitamin B12 as it passes through the stomach and enzymatically releases it in the duodenum where it is subsequently bound by intrinsic factor (IF) [@B15], [@B17], [@B18]. Interestingly, TCN1 has been reported to be overexpressed in some malignancies such as hepatocellular carcinoma (HCC) and cancers of the breast, lung and stomach [@B15], [@B17]-[@B24]. Recently, a bioinformatics -based study has suggested that *TCN1* as an important oncogene for the classification of normal and CRC tissues [@B25]. However, little is known about its expression in CRC and the clinical relevance, especially those related to CCRT, has not been systemically established.

In this study, we first identified*TCN1* as the most significantly upregulated gene of those involving glutamine metabolism, predicting poor response to neoadjuvant CCRT. Then, we evaluated the clinical correlates of TCN1 expression in a well-characterized study cohort of rectal cancer patients treated with neoadjuvant CCRT.

Materials and methods
=====================

Analysis of published transcriptome dataset
-------------------------------------------

To identify potential genes involving in response to neoadjuvant CCRT, one public transcriptome of 46 tissue samples from rectal patients receiving neoadjuvant CCRT (GSE35452) was analyzed using Human Genome U133 Plus 2.0 arrays from Affymetrix. The raw CEL files was computerized using statistical software Nexus Expression 3 (BioDiscovery). All probe sets were analyzed without pre-selection. Class comparison and functional profiling were conducted to recognize significant differentially expressed genes, with special attention to pathways involving ion transport-related genes (GO:0006811). We selected those with *p*\<0.01 and alteration of log 2-transformed expression at least +/-0.1-fold for further analysis.

Patients and tumor specimens
----------------------------

We procured formalin-fixed paraffin-embedded (FFPE) tissue specimens from 172 rectal cancer patients with regular follow-up from the archive of Chi Mei Medical Center between 1998 and 2004. This study was approved by the institutional review board (IRB 10302014). All patients were pathologically diagnosed with a rectal adenocarcinoma using a colonendoscopic biopsy, lacking evidence of distant metastasis on imaging examination including chest X-radiography and/or abdominopelvic CT. The criteria for the clinicopathologic evaluation were essentially identical as previously described [@B26]-[@B28]. In general, all patients received had preoperative 5-fluorouracil-baed chemotherapy concomitant to radiotherapy with a total dose of 45 Gy in 25 fractions over a period of five weeks. Adjuvant systemic chemotherapy was boosted if the pre-treatment (Pre-Tx) or post-treatment (Post-Tx) tumor or nodal status was beyond T3 or N1, respectively. All patients were regularly monitored after diagnosis until death or last follow-up.

Histopathologic evaluation
--------------------------

The pathologic examination of the tumor specimen was evaluated by two pathologists (CF Li and YC Wei) in a blinded manner without prior knowledge of the clinical information. Post-Tx T and N stages of all patients were classified according to the American Joint Committee on Cancer (AJCC) staging manual, 7th edition [@B29]. Tumor regression grade (TRG) in response to neoadjuvant CCRT is used as the end-point with the histologic assessment described previously [@B30].

TCN1 immunohistochemistry analysis
----------------------------------

Immunohistochemistry of FFPE tissue sections was performed as previously described [@B26]-[@B28]. Briefly, tissue sections from Pre-Tx rectal tumor biopsies were deparaffinized and rehydrated for TCN1 immunostaining. A blockade of the endogenous peroxidase activity was performed with 3% H2O2 for 10 minutes. Slides were washed with Tris buffered saline for 15 min after blocking and then incubated with a primary anti-TCN1 monoclonal antibody (ab118386, Abcam). The TCN1 staining was interpreted using the H-score, defined by the following equation: H-score = ΣPi (i + 1) as previously described [@B31]-[@B34]. The staining intensity of the decorated tumor cells was graded from "0 to 3+", and Pi is the percentage of the stained tumor cells with various intensities. Tumors with no less than the median of all scored cases were defined as showing high expression of TCN1. Immunohistochemically, TCN1 has been found to be localized to the membrane and cytoplasm of tumor cells [@B17], [@B24].

Statistical analysis
--------------------

All statistical analysis was carried out using SPSS 14 software package. The association of TCN1 expression with clinicopathologic features were conducted using Chi-square test. Rectal cancer-specific survivals including disease-specific survival (DSS), local recurrence-free survival (LRFS), and metastasis-free survival (MeFS) as the endpoints analyzed were calculated as the time interval between the date of surgery and the date of event developed as described in our previous work [@B35]. Survival curves were plotted by the Kaplan-Meier method and compared using the log-rank tests to evaluate prognostic differences between subgroups. Those parameters demonstrated prognostic significance at univariate level were determined by the Cox multivariate regression analysis. A two tailed p\<0.05 was considered to be statistically significant for all analyses.

Results
=======

Upregulation of TCN1 gene predicts poor response to CCRT
--------------------------------------------------------

From the dataset of 46 rectal cancer cases in a public transcriptome GSE35452, we focused on genes related to ion transport (GO:0006811). In non-responders to CCRT, only TCN1 showed significant upregulation (Table-[1](#T1){ref-type="table"} and Figure-[1](#F1){ref-type="fig"}). We found that there were ten genes significantly identified in non-responders to CCRT, including *TCN1, PLLP, SCNN1A, BEST2, AKAP7, GABRA2, FXYD3, CACNB2, KCNJ2, and TRPM4* (Figure [1](#F1){ref-type="fig"} and Table [1](#T1){ref-type="table"}). Among these downregulated genes, *TCN1* exhibited the top-ranking, upregulated fold change (log2 ration=1.5459, *p*=0.0003) (Table [1](#T1){ref-type="table"}). It promoted us to further investigate the expression status and clinical relevance of TCN1 in rectal cancers.

Immunohistochemical expression of TCN1 and its association with clinicopathologic features
------------------------------------------------------------------------------------------

To evaluate the relationship between TCN1 expression levels and clinicopathologic characteristics of rectal cancers treated with neoadjuvant CCRT, immunohistochemistry was performed to examine the expression of TCN1 in 172 rectal cancer specimens. Cytoplasmic expression of TCN1 was successfully scored in all examined cases with a wide range of H-scores, varying from 100 to 290 (Figure-[2](#F2){ref-type="fig"}). As summarized in Table-[2](#T2){ref-type="table"}, TCN1 upregulation was correlated with an advanced Post-Tx tumor and nodal status (Both *p*\<0.001) as well as the presence of vascular invasion (*p*=0.003). Moreover, TCN1 overexpression was found to be significantly associated with lesser degree of tumor regression (*p*\<0.001). In the group of high TCN1 expression, there were 27 (15.7%) patients with tumor regression grade 0-1, 58 (33.7%) patients with grade 2-3, and 1 (0.6%) patients with grade 4. In the group of low TCN1 expression, by contrast, there were 10 (5.8%) patients with tumor regression grade 0-1, 60 (34.9%) patients with grade 2-3, and 16 (9.3%) patients with grade 4.

Prognostic impact of TCN1 expression in rectal cancer
-----------------------------------------------------

In addition, we analyzed the prognostic significance of TCN1 expression in patients with rectal cancer. The mean follow-up time of these patients was 48.2 months (range, 6.2 to 131.2). At the univariate level, clinicopathologic parameters including the Pre-Tx tumor and positive lymph node metastasis, Post-Tx tumor and nodal statuses, presence of vascular invasion, and TRG were predictive of at least one of the three endpoints of this study (Table-[3](#T3){ref-type="table"}). Notably, patients with high expression of TCN1 were characterized by a more aggressive clinical course, with significantly poorer DSS (*p*\<0.0001; Figure-[3](#F3){ref-type="fig"}), LRFS (*p*=0.0001; Figure-[3](#F3){ref-type="fig"}) and MeFS (*p*=0.0002; Figure-[3](#F3){ref-type="fig"}). At multivariate comparisons, TRG and TCN1 expression remained to be shown as independent prognostic factors. High expression of TCN1 was independent predictive for DFS (*p*=0.002, hazard ratio=3.344), LRFS (*p*=0.037, hazard ratio=3.037) and MeFS (*p*=0.021, hazard ratio=3.015) (Table-[4](#T4){ref-type="table"}).

Discussion
==========

During the last decades, there has a great improvement in the care of patients with LARC and neoadjuvant CCRT followed by surgery is the current standard treatment strategy [@B3]-[@B6]. Unfortunately, current treatment for LARC patients with neoadjuvant CCRT demonstrates disappointing results [@B7], [@B8]. Therefore, it is essential to develop effective predictive biomarkers, not only for prognostication, but also to individualize treatment for patients with rectal cancers. In the present study, we have shown that overexpression of TCN1 was correlated with aggressive biological behaviors and poor clinical outcomes in rectal cancers. In accordance with the pathologic variable analysis, there was a strong correlation with poor survivals including DFS, LRFS and MeFS. Moreover, overexpression of TCN1 was predictive of low tumor regression after neoadjuvant CCRT, suggesting that TCN1 could be a potential therapeutic target of rectal cancers and/or could be a biomarker for monitoring the efficiency of therapy.

TCN1 is a 60-70 kDa molecular weight protein, derived from the granulocyte line [@B36], [@B37]. TCN1 participates in vitamin B12 homeostasis together with another two vitamin B12 binding proteins (intrinsic factor and TCN2) [@B38]. Elevated serum levels of vitamin B12 and TCN1 have been reported in patients with cancers [@B18], [@B21], [@B39]. Furthermore, it has been well elucidated the associations between high serum levels of vitamin B12 and malignant hematological diseases such as chronic myeloid leukemia and acute leukemia and the pathogenesis involves release of TCN1 by proliferating granulocytes [@B36], [@B37], [@B40]. In addition, upregulation of TCN1 both in plasm and tumor tissue have been reported in a number of solid neoplasms including HCC, salivary gland tumors, cancers of the breast, kidney, lung and stomach, and endocervical adenocarcinoma [@B15], [@B17]-[@B24], [@B41]. Previous studies have suggested that increased serum level and expression of TCN1 in patients with HCC or secondary liver metastasis might be due to a diminished clearance of TCN1 in the liver [@B38], [@B42]. On the other hand, overexpression of TCN1 in other solid malignancies has been inferred mainly to be an excess synthesis of its production by tumor cells themselves or to an increase of hypergranulocytosis [@B17], [@B36], [@B38]. Moreover, TCN1 rather than vitamin B12 was found to be better correlated with progression in patients with gastric cancer [@B20]. Chu et al recently identified TCN1 as a significantly expressed gene that is associated with advanced CRC by microarray meta-analysis [@B25]. Our results of the present study provide additional evidence that expression status of TCN1 was more produced in tumor cells in parallel to previous research works, suggesting TCN1 as a marker of disease progression in CRC.

Vitamin B12, an ubiquitous coenzyme mainly involving the synthesis of DNA, plays an important role in cell division and cellular metabolism [@B36], [@B43]. Elevated serum vitamin B12 levels have been found to be associated with increased cancer risk and mortality risk in both cancer and non-cancer patients [@B40], [@B44], [@B45]. Some studies have also suggested the degree of elevated plasm vitamin B12 level as a poor prognosticator in certain tumors, particularly of the liver [@B46], [@B47]. The mechanisms implicated in the genesis of elevated serum vitamin B12, as addressed above, might be due to a decrease in hepatic clearance or an increase in TCN1 production [@B36], [@B40]. Monitoring of serum vitamin B12 and TCN1 may be of specific clinical value in both the initial and subsequent evaluation of response to treatment in patients associated with increased vitamin B12-binding protein synthesis [@B21]. In addition, rapidly dividing cells such as cancer cells need certain vitamins including vitamin B12, folic acid, biotin and riboflavin for tumor growth and survival [@B48], [@B49]. It has been reported that receptors involved in vitamin B12-binding and uptake, including TCN1 and TCN2, are overexpressed in various malignancies [@B15], [@B17]-[@B24], [@B41], [@B49]. Previous studies showed that TCN2 involving one-carbon metabolism pathway was associated with increased risk of colorectal adenoma but the relationship between TCN2 and CRC was inclusive [@B50]-[@B52]. In the present study, we demonstrated that TCN1 was expressed in rectal cancers and its overexpression was associated with advanced disease status. Waibel et al [@B17] suggested the use of a new synthetic cobalamin analog specifically to bind to TCN1 instead of TCN2 to deliver vitamin-conjugated compounds to tumor sites. In their study, high expression of TCN1 immunohistochemistry was found in various kinds of tumors including colorectal cancers, findings in parallel to the present study results [@B17]. Thus, we hypothesized that tumors might express vitamin B12 -binding proteins such as TCN1 to satisfy the high demand of cobalamin. Accordingly, vitamin B12 could be as a potential targeting agent in both CRC diagnosis and anticancer therapy through TCN1-mediated binding [@B17], [@B48], [@B49].

Several issues must be considered in the present study. First, we did not investigate endogenous TCN1 mRNA and protein levels in CRC through Western blot or reverse transcription polymerase chain reaction that could further support the observed overexpression of TCN1 as a poor prognostic factor. Second, we did not evaluate the pre-and post-treatment serum levels of cobalamin and TCN1 in our patient cohort, partially owing to an incomplete per-operative study. Although a high level of TCN1 in plasma is not specific to CRC cancer, its decrease after therapeutic intervention may be useful in monitoring the clinical course of the disease. A large-scale study may be required to clarify the association between the serum levels of cobalamin and TCN1 and expression of TCN1 in CRC.

In summary, this study was the first to demonstrate that overexpression of TCN1 was closely associated with low tumor regression and an aggressive biological behavior of patients with rectal cancers receiving neoadjuvant CCRT. The strong inverse correlation with survivals in rectal cancer suggested that overexpression of TCN1 was an independent negative prognosticator. In addition, a better understanding of the role of TCN1 expression in rectal cancer and its relationship with CCRT effect may have potential as a prognostic and therapeutic target.
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![Analysis of gene expression in CCRT responders versus non-responders from a published transcriptomic dataset of rectal cancers. Clustering analysis of genes related to iron transport shows TCN1 is significantly upregulated in patients responsive to CCRT. Tissue specimens from non-responders (blue lines) and responders (yellow lines) are indicated on top of the heatmap, and expression levels of upregulated and downregulated genes are expressed as a spectrum of brightness of red and green, respectively, with those unaltered in mRNA](jcav08p1330g001){#F1}

![Representative immunostainings of TCN1 expression. The non-neoplastic colonic mucosa (A) reveals no expression of TCN1 as compared with rectal cancers with low expression (B) and high expression (C) of TCN1 in pre-treatment specimens.](jcav08p1330g002){#F2}

![Kaplan-Meier survival curves plotted to predict survival. Using the log-rank test, high expression of TCN1 predicts inferior disease-specific survival (A) as well as local recurrence-free survival (B). It also significantly predicts metastasis-free survival (C).](jcav08p1330g003){#F3}

###### 

Summary of differentially expressed genes associated with ion transport (GO:0006811) in relation to response to CCRT in rectal carcinoma

  Probe          Comparison log ratio   Comparison p-value   Gene Symbol   Gene Name                                                            Biological Process                                                                                                               Molecular Function
  -------------- ---------------------- -------------------- ------------- -------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  205513_at      1.5459                 0.0003               *TCN1*        transcobalamin I (vitamin B12 binding protein; R binder family)      cobalamin transport, cobalt ion transport, ion transport, transport                                                              cobalamin binding, cobalt ion binding, cobalt ion transmembrane transporter activity
  204519_s\_at   1.1474                 \<0.0001             *PLLP*        plasma membrane proteolipid (plasmolipin)                            ion transport, transport                                                                                                         ion channel activity
  203453_at      1.1402                 0.0001               *SCNN1A*      sodium channel; nonvoltage-gated 1 alpha                             excretion, ion transport, response to stimulus, sodium ion transport, transport                                                  amiloride-sensitive sodium channel activity, ion channel activity, protein binding, sodium channel activity, sodium ion binding
  207432_at      0.8953                 0.0004               *BEST2*       bestrophin 2                                                         ion transport, transport                                                                                                         calcium ion binding, chloride channel activity, chloride ion binding, ion channel activity
  205771_s\_at   0.8460                 0.0013               *AKAP7*       A kinase (PRKA) anchor protein 7                                     intracellular signaling cascade, ion transport, protein localization                                                             kinase activity, protein kinase A binding
  207014_at      0.8246                 0.0001               *GABRA2*      gamma-aminobutyric acid (GABA) A receptor; alpha 2                   chloride transport, gamma-aminobutyric acid signaling pathway, ion transport, regulation of neurotransmitter levels, transport   GABA-A receptor activity, benzodiazepine receptor activity, chloride channel activity, chloride ion binding, extracellular ligand-gated ion channel activity, ion channel activity, neurotransmitter receptor activity
  202488_s\_at   0.8124                 0.0005               *FXYD3*       FXYD domain containing ion transport regulator 3                     chloride transport, ion transport, transport                                                                                     chloride channel activity, chloride ion binding, ion channel activity
  202489_s\_at   0.5951                 0.0018               *FXYD3*       FXYD domain containing ion transport regulator 3                     chloride transport, ion transport, transport                                                                                     chloride channel activity, chloride ion binding, ion channel activity
  213714_at      0.5807                 0.0001               *CACNB2*      calcium channel; voltage-dependent; beta 2 subunit                   calcium ion transport, ion transport, neuromuscular junction development, transport                                              calcium channel activity, calcium ion binding, ion channel activity, voltage-gated calcium channel activity, voltage-gated ion channel activity
  206765_at      0.5684                 0.0093               *KCNJ2*       potassium inwardly-rectifying channel; subfamily J; member 2         ion transport, potassium ion transport, transport                                                                                inward rectifier potassium channel activity, ion channel activity, potassium ion binding, protein binding, voltage-gated ion channel activity
  219360_s\_at   0.5391                 0.0057               *TRPM4*       transient receptor potential cation channel; subfamily M; member 4   immune response, ion transport, transport                                                                                        ATP binding, calcium ion binding, calmodulin binding, ion channel activity, nucleotide binding, receptor activity

###### 

Associations and comparisons between TCN1 expression and clinicopathological factors in 172 rectal cancer patients receiving neoadjuvant CCRT.

  Parameter                                    No.   TCN1 Expression   *p*-value   
  ------------------------------- ------------ ----- ----------------- ----------- -----------
  Gender                          Male         108   54                54          1.000
                                  Female       64    32                32          
  Age                             \<70         106   48                58          0.117
                                  ≧70          66    38                28          
  Pre-Tx tumor status (Pre-T)     T1-T2        81    41                40          0.879
                                  T3-T4        91    45                46          
  Pre-Tx nodal status (Pre-N)     N0           125   68                57          0.060
                                  N1-N2        47    18                29          
  Post-Tx tumor status (Post-T)   T1-T2        86    57                29          \<0.001\*
                                  T3-T4        86    29                57          
  Post-Tx nodal status (Post-N)   N0           123   74                49          \<0.001\*
                                  N1-N2        49    12                37          
  Vascular invasion               Absent       157   84                73          0.003\*
                                  Present      15    2                 13          
  Perineural invasion             Absent       167   85                82          0.173
                                  Present      5     1                 4           
  Tumor regression grade          Grade 0-1    37    10                27          \<0.001\*
                                  Grade 2\~3   118   60                58          
                                  Grade 4      17    16                1           

\*, statistically significant

###### 

Univariate log-rank analysis for important clinicopathological variables and TCN1 expression

  Parameter                                    No. of case   DFS   LRFS         MeFS                   
  ------------------------------- ------------ ------------- ----- ------------ ------ ---------- ---- ----------
  Gender                          Male         108           34    0.6344       20     0.2250     17   0.3520
                                  Female       64            20                 7                 14   
  Age                             \<70         106           35    0.6999       18     0.6615     20   0.7427
                                  ≧70          66            19                 9                 11   
  Pre-Tx tumor status (Pre-T)     T1-T2        81            20    0.0486\*     10     0.2261     11   0.1745
                                  T3-T4        91            34                 17                20   
  Pre-Tx nodal status (Pre-N)     N0           125           33    0.0010\*     15     0.0070\*   19   0.0973
                                  N1-N2        47            21                 12                12   
  Post-Tx tumor status (Post-T)   T1-T2        86            15    0.0002\*     7      0.0040\*   8    0.0033\*
                                  T3-T4        86            39                 20                23   
  Post-Tx nodal status (Post-N)   N0           123           35    0.2338       16     0.1320     20   0.4634
                                  N1-N2        49            19                 11                11   
  Vascular invasion               Absent       157           45    0.0029\*     21     0.0028\*   27   0.4470
                                  Present      15            9                  6                 4    
  Perineural invasion             Absent       167           51    0.0647       25     0.0940     30   0.9083
                                  Present      5             3                  2                 1    
  Tumor regression grade          Grade 0-1    37            23    \<0.0001\*   10     0.0090\*   14   0.0006\*
                                  Grade 2\~3   118           30                 17                16   
                                  Grade 4      17            1                  0                 1    
  TCN1 expression                 Low Exp.     86            10    \<0.0001\*   5      0.0001\*   6    0.0002\*
                                  High Exp.    86            44                 22                25   

DFS, disease-free survival; LRFS, local (pelvic) recurrence-free survival; MeFS, metastasis-free survival; \*, statistically significant

###### 

Multivariate analysis

  Parameter                       DFS     LRFS          MeFS                                                            
  ------------------------------- ------- ------------- --------- ------- ------------- --------- ------- ------------- ---------
  Tumor regression grade          2.381   1.360-4.167   0.002\*   1.992   0.906-4.386   0.087     2.096   1.008-4.237   0.048\*
  TCN1 expression                 3.344   1.572-7.116   0.002\*   3.037   1.062-8.685   0.037\*   3.015   1.177-7.721   0.021\*
  Vascular invasion               1.783   0.806-3.943   0.153     1.958   0.715-5.364   0.191     \-      \-            \-
  Post-Tx tumor status (Post-T)   1.382   0.730-2.616   0.320     1.701   0.686-4.216   0.251     1.766   0.752-4.149   0.192
  Pre-Tx nodal status (Pre-N)     1.467   0.759-2.838   0.254     2.007   0.864-4.661   0.105     \-      \-            \-
  Pre-Tx tumor status (Pre-T)     1.476   0.770-2.827   0.241     \-      \-            \-        \-      \-            \-

DFS, disease-free survival; LRFS, local (pelvic) recurrence-free survival; MeFS, metastasis-free survival; \*, statistically significant
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